drugset
drugset / Trial / NCT00512681

A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer

NCT00512681 ↗

Phase 2 Completed 44 enrolled National Cancer Center, Korea
NaSingle-groupOpen-labelTreatment

Summary

Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1 and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessement will be performed every 2 cycles of chemotherapy.

Timeline

Start
2007-07
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject TS-1 Small molecule 40 mg/m2 Oral
Subject TS-1 Small molecule 80 mg/m2 Oral

Indications

gastric neoplasm